Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 12:01 save search
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer
Published: 2023-05-31 (Crawled : 12:01) - prnewswire.com
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: -3.25%
prgn-2009 fda cancer clearance immunotherapy study
Aspira Women’s Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
AWH | $3.53 0.71% 7K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.43%
health cancer publication risk
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
Published: 2020-12-14 (Crawled : 12:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
breast cancer cancer preclinical pre-clinical
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
Published: 2020-12-07 (Crawled : 12:01) - globenewswire.com
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -1.17%
H: 2.55%
C: -2.97%
cancer phase 2 agx148
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.